These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6396321)

  • 1. Serum and sputum concentrations of azlocillin, cefoperazone and ceftazidime in patients with cystic fibrosis.
    Martini N; Agostini M; Barlocco G; Bozzini L; Castellani L; Messori A; Scroccaro G; Mastella G
    J Clin Hosp Pharm; 1984 Dec; 9(4):303-9. PubMed ID: 6396321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
    Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of latamoxef, cefoperazone and piperacillin into the sputum of patients with cystic fibrosis.
    Laferriere C; Stutman HR; Marks MI; Kramer J; Flux M
    Chemotherapy; 1985; 31(4):255-60. PubMed ID: 3928280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis.
    Turner A; Pedler SJ; Carswell F; Spencer GR; Speller DC
    J Antimicrob Chemother; 1984 Nov; 14(5):521-7. PubMed ID: 6392281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azlocillin and gentamicin in respiratory tract infections with Pseudomonas aeruginosa in patients with cystic fibrosis.
    Malmborg AS; Alfredsson H; Kusoffsky E; Strandvik B
    Scand J Infect Dis Suppl; 1981; 29():64-9. PubMed ID: 6947407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of high-dose azlocillin sodium in patients with cystic fibrosis.
    Woolf RA; Koup JR; Smith AL; Hilman BC; Goldmann D; Williams-Warren J
    Clin Pharm; 1985; 4(6):664-9. PubMed ID: 4075734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Azlocillin treatment of Pseudomonas aeruginosa bronchopulmonary infections in children with cystic fibrosis].
    Grenier B; Gilly R
    Presse Med; 1984 Mar; 13(13):815-8. PubMed ID: 6231602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis.
    Hjelte L; Malmborg AS; Strandvik B
    J Antimicrob Chemother; 1989 Jun; 23(6):885-90. PubMed ID: 2503488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azlocillin pharmacokinetics in patients with cystic fibrosis.
    Bosso JA; Saxon BA; Herbst JJ; Matsen JM
    Antimicrob Agents Chemother; 1984 May; 25(5):630-2. PubMed ID: 6732230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azlocillin in cystic fibrosis.
    Malmborg AS; Alfredsson H; Strandvik B
    Isr J Med Sci; 1983 Nov; 19(11):1001-3. PubMed ID: 6662681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Azlocillin in the treatment of pulmonary infections in patients with cystic fibrosis: plasma concentrations and therapeutic indications].
    Rosselli P; Marianelli L; Valenza T; Bartolozzi G
    Pediatr Med Chir; 1989; 11(4):389-91. PubMed ID: 2694104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ceftazidime absorption into bronchial secretions in mucoviscidosis patients].
    Berthelot G; Lenoir G; Grenier B; Tournier G; Sardet A; Steru D; Bergogne-Berezin E
    Pathol Biol (Paris); 1985 May; 33(5):430-4. PubMed ID: 3897974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of in vitro bacteriostatic effect of five betalactamins against Pseudomonas aeruginosa (author's transl)].
    Lesage D; Delisle-Mizon F; Denis C; Vergez P; Daguet GL
    Pathol Biol (Paris); 1982 Jun; 30(6):440-3. PubMed ID: 6213917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.
    Giwercman B; Meyer C; Lambert PA; Reinert C; Høiby N
    Antimicrob Agents Chemother; 1992 Jan; 36(1):71-6. PubMed ID: 1590704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of azlocillin in children with and without cystic fibrosis treated for infectious diseases.
    Michalsen H; Bergan T
    Methods Find Exp Clin Pharmacol; 1986 Dec; 8(12):727-9. PubMed ID: 3807473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime disposition in acute and stable cystic fibrosis.
    Leeder JS; Spino M; Isles AF; Tesoro AM; Gold R; MacLeod SM
    Clin Pharmacol Ther; 1984 Sep; 36(3):355-62. PubMed ID: 6432400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.
    Dalzell AM; Sunderland D; Hart CA; Heaf DP
    Thorax; 1991 Apr; 46(4):239-41. PubMed ID: 1903896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum.
    Ramphal R; Lhermitte M; Filliat M; Roussel P
    J Antimicrob Chemother; 1988 Oct; 22(4):483-90. PubMed ID: 3060459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
    Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
    J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.